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Abstract: Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase 
inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class 
of agent in this disease. Three TKIs are currently approved for use in patients with advanced disease. Newer, more potent inhibitors have 
reached phase III clinical testing, meaning others are likely to follow. In 2009, pazopanib became the most recent TKI to receive FDA 
approval. This review sets out to discuss the key opportunities and challenges associated with TKI use in RCC, focusing particularly 
on pazopanib. We also review the current place of pazopanib in the management of patients with advanced disease, in what is a rapidly 
evolving therapeutic landscape.
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Introduction
Renal cancer
Renal  cell  carcinoma  (RCC)  accounts  for  2%–3% 
of all adult malignancies, with an estimated 270,000 
new cases and 116,000 deaths worldwide each year.1 
Incidence rates vary substantially across the world, 
with  higher  rates  observed  in  North America  and 
Europe in comparison to Asia and Africa. After over 
two  decades  of  increasing  rates,  RCC  worldwide 
incidence trends show signs of plateauing or decreas-
ing in recent years.2 The most common histological 
subtype of RCC is the conventional or clear cell type 
accounting for 70%–80% of cases. The rest are com-
posed of papillary, chromophobe, and collecting duct 
tumors although accurate histological distinction is 
not always possible.3
Central to the biology of sporadic clear cell RCC 
is loss of function of the Von Hippel Lindau (VHL) 
tumor suppressor gene, located on chromosome 3p. 
Recent comprehensive genetic studies suggest very 
high  rates  (.95%)  of  VHL  involvement  through 
mutation,  methylation  and  loss  of  heterozygosity 
analysis such that VHL loss of function may provide 
a molecular basis for classification as clear cell RCC.4 
The  VHL  gene  products  function  in  the  hypoxia 
inducible pathway, forming a multiprotein complex 
that  principally  functions  to  ubiquitinate  hypoxia 
inducible factor-alpha (HIF-α) leading to its protea-
somal degradation.
HIF is a heterodimeric transcription factor con-
sisting of an unstable α subunit and a stable beta (β) 
subunit.  Under  low  oxygen  conditions  or  in  cells 
lacking pVHL, HIF-α accumulates, binds to HIF-β, 
and transcriptionally activates genes whose promot-
ers  contain  hypoxia-response  elements.  Up  to  100 
HIF-responsive  genes  have  been  described,  many 
of which are involved in the adaptation to acute or 
chronic hypoxia.5 These include glucose transporters 
(eg, GLUT1) and growth factors such as transforming 
growth factor-α, as well as the highly pro-angiogenic 
factors  vascular  endothelial  growth  factor  (VEGF) 
and platelet-derived growth factor (PDGF). RCCs are 
characterised as being highly vascular tumors, driven 
by VEGF-dependent angiogenesis. Angiogenesis, the 
growth of new vessels from pre-existing vasculature, 
is a critical step in tumor progression.6 Inhibition of 
the VEGF pathway has proven a highly effective ther-
apeutic strategy in RCC, improving the outlook for 
patients with advanced disease. This may be achieved 
via  monoclonal  antibodies  targeted  to  bind  VEGF 
(eg, bevacizumab) or through intracellular inhibition 
of VEGF signalling through the use of small mole-
cule tyrosine-kinase inhibitors (TKIs) that target the 
intracellular kinase domains of the VEGF receptors 
(VEGFR1-3). Receptor tyrosine kinases are essential 
for the transduction of extracellular signals into the 
cell. A receptor tyrosine kinase monomer consists of 
an N-terminal extracellular ligand-binding domain, 
a transmembrane domain, and a C-terminal intracel-
lular domain with tyrosine kinase activity. The kinase 
domain has a bi-lobar structure, with an ATP-binding 
cleft located between the N- and C-terminal lobes.7
Tyrosine kinase inhibitors
Since  the  approval  six  years  ago  of  the  first  TKI 
for RCC, these agents have gone on to become the 
most successful class of drug used in the treatment 
of this disease. They are classed as anti-angiogenic 
agents, thought primarily to function by inhibiting 
tumor  endothelial  growth  and  survival  signalling. 
Three TKIs  are  currently approved  in  the  US  and 
Europe: sorafenib (Nexavar; Bayer Pharmaceuticals), 
  sunitinib (Sutent; Pfizer Inc) and pazopanib (Votrient; 
  GlaxoSmithKline). Two others, axitinib (AG-013736; 
Pfizer Inc) and tivozanib (AV-951; Aveo Pharmaceu-
ticals), have reached phase III clinical testing. A sum-
mary of these agents is presented in Table 1.
Sunitinib was granted Food and Drug Administra-
tion (FDA) approval in January 2006 and still rep-
resents the current standard of care in the first line 
metastatic setting. In a landmark randomized phase III 
study, sunitinib doubled median progression-free sur-
vival (PFS) in comparison to interferon-α (the then 
standard) from 5 months to 11 months amongst 750 
patients with metastatic RCC (mRCC) (Hazard Ratio 
(HR) 0.42 (95% confidence interval, 0.32 to 0.54; 
P , 0.001), with median overall survival (OS) of .2 
years.8,9 Sorafenib, FDA approved in October 2005, 
improved PFS from 2.8 months to 5.5 months versus 
placebo (P , 0.01) amongst 903 cytokine refractory 
patients.10 From these initial, and subsequent, stud-
ies, however, it became clear that the TKIs presented 
their own set of challenges. Firstly, the TKIs were 
associated with a number of common toxicities. Sec-
ondly, resistance was observed, either intrinsically or 
otherwise invariably acquired. Thirdly, there was a TKIs in advanced renal cell carcinoma
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lack of predictive biomarkers of response. Fourthly, 
assessment of response by standard Response Evalu-
ation Criteria In Solid Tumors (RECIST) was recogn-
ised as inadequate. And finally, what, if any, sequence 
in which to use these drugs was unclear.
Common to all currently used TKIs is that they are 
multi-targeted agents, inhibiting a number of recep-
tor  kinases  including  PDGFR  α  and  β,  stem  cell 
factor receptor (KIT), RET and FMS-like tyrosine 
kinase-3 (Flt-3) in addition to VEGFRs, with vary-
ing potency.11 This lack of specificity brings with it 
a number of common side-effects, often termed ‘off-
target’ effects, including hypothyroidism, hand-foot 
syndrome, diarrhea, stomatitis and anorexia. Others, 
such as hypertension and lethargy, may in fact repre-
sent ‘on-target’ toxicities. Thus many patients require 
dose reductions (or stop therapy altogether), which 
may negatively impact on both quality of life and 
survival.12 This has led to the introduction of a new 
generation of TKIs such as axitinib and tivozanib that 
have a much higher potency and selectivity for VEG-
FRs which, it is hoped, will lead to better tolerated 
and more efficacious therapy.
No  matter  how  potently  the  VEGF  pathway  is 
blocked,  resistance  to  TKIs  invariably  develops, 
typically within months of commencing therapy. The 
underlying mechanisms behind this are poorly under-
stood. Resistance is likely to be a process that involves 
complex  tumor-stromal  interactions.  A  number  of 
mechanisms have been proposed which remain under 
investigation.13 Possibilities include the increased pro-
duction of alternative pro-angiogenic growth factors,14 
acquired tumor cell resistance15 and inflammatory cell 
infiltration.16 The observation of responses following 
sunitinib re-challenge17 or with sequential TKI use18 
are intriguing and further raise the possibility that 
such mechanisms are reversible. Unlike other tumor 
types treated with targeted therapies, there remains a 
lack of biomarkers that allow prediction of response 
to TKIs amongst individual patients with RCC. Such 
markers are important to avoid unnecessary toxic-
ity and potentially carry important health economic 
benefits.
In October 2009, pazopanib became the third and 
most  recently  approved  TKI  for  use  in  advanced 
RCC by the FDA. In the UK, the National Institute 
for Clinical Excellence (NICE) approved its use in 
the first line setting for patients with metastatic RCC 
and Eastern Cooperative Oncology Group (ECOG) 
performance status 0–1. This review will focus on the 
key clinical data supporting the use of this drug and 
attempt to interpret this data in the context of what is 
a rapidly evolving therapeutic landscape.
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Pazopanib  hydrochloride  is  an  orally  bioavailable, 
multi-targeted TKI that inhibits the function of multiple 
receptor kinases including VEGFR1-3, PDGFRα/β, 
fibroblast growth factor receptor 1, 3 and 4 (FGFR), 
KIT, and RET. A comparison of TKIs currently used 
in RCC, their kinase targets and inhibitory concentra-
tions has recently been reported by Cowey et al.19 Such 
comparisons of relative potency, as measured by IC50 
against VEGFR2, suggest that pazopanib (30 nmol) 
is comparable to sunitinib (10 nmol) and sorafenib 
(90 nmol) in this regard. However pazopanib may 
have a narrower target range, with a quicker drop-off 
in terms of off-target inhibition.19
Pazopanib is taken on a continuous cycle at a dose 
of 800 mg daily, based on Phase I data.20 Its half-life 
is approximately 30 hours and time to peak plasma 
concentration is between 2 and 4 hours.20 It is metab-
olised by cytochrome P450 3A4 (CYP3A4) and hence 
Table 1. TKIs approved or in phase III testing for use in RCC.
pFs (months) Dose schedule
Treatment naive cytokine refractory
Pazopanib27 11.1 7.4 800 mg od Continuous
Sunitinib8,59 11.0 8.3 50 mg od 4 wks on/2 wks off
Sorafenib10,60 5.7 5.5 400 mg bd Continuous
Axitinib57 NA 12.1 5 mg bd Continuous
Tivozanib58 14.3 15.8 1.5 mg od Continuous
Abbreviations: NA, Not available; PFS, Progression Free Survival.vasudev and Larkin
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patients  must  avoid  concomitant  use  with  strong 
inhibitors and inducers of this enzyme. Elimination is 
primarily via feces with renal elimination accounting 
for ,4% of the administered dose.21
Crushing tablets or taking oral suspension incr-
eases  plasma  concentration  approximately  100% 
and 29% respectively, and decreased time to achieve 
maximum  plasma  concentration  (by  approximately 
2 h and 1 h respectively), indicating increased rate 
and extent of oral absorption relative to whole-tablet 
administration.22 A similar effect is observed follow-
ing   administration of pazopanib with low- and high-
fat meals, such that the drug should ideally be taken 
at least one before or two hours after a meal.21,23
Clinical Efficacy
The phase I20 and II24 data for pazopanib have been 
summarized  elsewhere.25,26  The  phase  III  study 
(VEG105912) of pazopanib that led to its approval 
was a placebo-controlled, randomized, double-blind, 
multi-center study.27 Patients were required to have 
clear-cell  or  predominantly  clear  cell  histology, 
ECOG PS #1 and could be either treatment naïve or 
have progressed on prior cytokine therapy. Patients 
were  randomized  2:1  to  receive  either  pazopanib 
800  mg  od  or  placebo.  Cross-over  at  progression 
was  allowed,  such  that  patients  on  placebo  could 
subsequently  receive  active  drug  (extension  trial, 
VEG107769). The primary end-point of the study 
was PFS.
435 patients were enrolled, with 290 and 145 patients 
in the pazopanib and placebo arms   respectively. The 
two  arms  were  well  matched,  with  53%  and  54% 
patients being treatment naïve amongst pazopanib and 
placebo treated cohorts. 94% of patients were good or 
intermediate prognosis as per Memorial Sloan Ketter-
ing Cancer Center (MSKCC) criteria.
Pazopanib  significantly  prolonged  PFS  in  com-
parison to placebo (median PFS 9.2 months   versus 
4.2  months;  HR  0.46;  P  ,  0.0001)  amongst  all 
patients.  The  difference  was  more  pronounced 
amongst the subset of treatment naïve patients (PFS 
11.1 months versus 2.8 months; HR 0.40; P , 0.0001) 
than those pre-treated with cytokines (PFS 7.4 versus 
4.2 months; HR 0.54; P , 0.001). Response rate (by 
independent review) was 32% versus 4% amongst 
treatment naïve patients with a median duration of 
58.7 weeks. Final OS data have since been presented 
and showed a median OS of 22.9 vs. 20.5 months in 
the pazopanib and placebo arms respectively (HR: 
0.91; P = 0.224). However, OS was confounded by 
extensive crossover of placebo patients to pazopanib 
and  other  therapies.  More  placebo  than  pazopanib 
patients  received  subsequent  treatment  (66%  vs. 
30%,  respectively)  with  54%  of  placebo  patients 
crossing to pazopanib, some as early as week 6. Two 
independent  analyses  to  adjust  for  crossover  were 
conducted, IPCW (Inverse Probability of Censoring 
Weighted) and RPSFT (Rank Preserving Structural 
Failure Time) suggest an OS benefit with pazopanib 
(HR 0.5; P = 0.002 by IPCW and HR 0.43; P = 0.172 
by RPFST).28
Health-related quality of life (HRQoL) was also 
examined as part of the study, reporting no evidence 
of a clinically important difference between pazopanib 
and  placebo  treated  patients  at  each  assessment 
  timepoint. In a subsequent post hoc analysis, time to 
HRQoL deterioration and association of changes in 
HRQoL with response were analysed. No significant 
difference was found in terms of time to deteriora-
tion  of  HRQoL.  However,  patients  with  complete 
response or partial response experienced significantly 
less HRQoL deterioration than those with progressive 
disease (P , 0.001 and P = 0.0024 respectively).29
Patients with polymorphisms in genes that increase 
CYP3A4 expression, and therefore potentially lower 
plasma  drug  levels,  have  a  lower  response  rate  to 
pazopanib30  and  increased  plasma  concentrations 
of TKIs have been associated with better outcome 
in  patients  with  metastatic  RCC.31  Amongst  225 
pazopanib  treated  patients,  those  who  achieved  a 
trough plasma level of .20.6 µg/ml after 4 weeks of 
treatment had a better response rate (45% versus 18%) 
and PFS (49.4 weeks versus 20.3 weeks; P = 0.004) 
than those ,20.6 µg/ml.32
Data  regarding  the  efficacy  of  pazopanib  after 
prior  targeted  therapy  for  advanced  RCC  has  also 
recently been reported. In a phase II study, 44 patients 
with mRCC who had progressed on either sunitinib 
(n = 32) or bevacizumab (n = 12) received pazopanib 
second-line. Overall response rate was 20%, with a 
median PFS of  9.2 months.33 In a retrospective single-
institution series involving 88 patients, second-line 
pazopanib demonstrated activity, with a response rate 
of 42% and 18% amongst patients who had failed 
1 and .1 prior targeted therapy respectively (P = 0.02). TKIs in advanced renal cell carcinoma
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Median time to progression was 71 days. The patients 
were heavily pre-treated (median number of prior tar-
geted agents was 2, range 1–5) with 58% of patients 
having failed both TKI and mTOR based therapies. 
Almost one half of patients also had poor-risk disease 
by MSKCC criteria.34
safety
Within the phase III study of pazopanib, 14% of all 
patients  stopped  drug  due  to  adverse  events  (AE) 
(12% amongst treatment naïve patients). Compara-
tive discontinuation rates due to AEs are shown for 
all TKIs in Table 2, where available. The most com-
monly reported AEs were diarrhea, hypertension, nau-
sea, anorexia and vomiting. The most common grade 
3/4 AEs were hypertension (4%), diarrhea (3%) and 
asthenia (3%). The incidence of hemorrhagic events 
was 13% in the pazopanib arm compared to 5% in the 
placebo arm. 1% of patients had fatal AEs attribut-
able to pazopanib as assessed by the investigator.
Recently presented data suggests that the frequency 
of some, but not all, toxicities increase as plasma con-
centration of pazopanib increases. When considered 
as quartiles based on trough levels of pazopanib, inci-
dence of hand foot syndrome (all grades) rose from 
0% (Q1) to 24% (Q4). Similarly, diarrhea increased 
from 24% to 67% and hypertension from 58% to 78%. 
No significant difference was noted in incidence of 
fatigue, nausea and vomiting. The data are revealing 
and suggest dose reductions may be effective for cer-
tain side-effects, but for others, such as fatigue, may 
have minimal impact.35
The main toxicities associated with the TKIs are 
summarised in Table 3. Clearly, comparisons across 
clinical trials must be made with caution but, to date, 
only one head-to-head trial has been reported.56 It is 
evident that rates of hypertension and diarrhea are 
similar across all agents, with the exception of tivo-
zanib that appears to cause less diarrhea. Rates of 
fatigue appear to be lower with pazopanib than other 
  first-generation TKIs. Part of the explanation for this 
may lie in the fact that pazopanib is associated with low 
rates of thyroid dysfunction. Agents such as sunitinib 
have a reported incidence of between 53%–85%.36,37 
In  comparison,  amongst  578  RCC  patients  treated 
with pazopanib within phase II and III studies, hypo- 
and hyperthyroidism were diagnosed in just 3% and 
1% of patients respectively.38
In addition, it is evident that the incidence of hand-
foot syndrome in pazopanib treated patients is notably 
lower than that seen with sunitnib, sorafenib and axi-
tinib. Amongst .900 patients treated with pazopanib 
800 mg daily within 10 prospective clinical cancer 
trials, the incidence of all-grade and high-grade hand-
foot  syndrome  was  4.5%  and  1.5%  respectively. 
Interestingly,  the  incidence  of  all-grade  hand-foot 
syndrome was significantly higher in patients with 
RCC as compared to patients with non-renal malig-
nancies (7.8% vs. 2.4%, P value = 0.015).39
Pazopanib,  like  other  TKIs,  is  associated  with 
hepatotoxicity. 18% of patients in the phase III study 
had an elevation in alanine transaminase (ALT) $3x 
the upper limit of normal. Grade 3/4 elevation of ALT, 
AST and bilirubin occurred in 12%, 7% and 3% of 
patients  respectively.  Concurrent  elevation  of  both 
ALT and bilirubin is rare (,1%) but can lead to fatal 
hepatotoxicity. Patients’ liver function tests must there-
fore be monitored closely during treatment with dose 
reduction/interruption  if  transaminitis  occurs.  The 
underlying  mechanism  of  pazopanib  induced  hepa-
totoxicity remains unclear. In the meantime, efforts 
have focused on identifying patients predisposed to 
hepatic  dysfunction.  Xu  and  colleagues  examined 
6852 polymorphisms in 282 candidate genes amongst 
115  pazopanib-treated  white  patients  with  RCC. 
  Polymorphisms  in  the  hemochromatosis  gene  were 
found to be significantly associated with elevations of 
ALT, with the rs2858996 TT genotype having an odds 
ratio for ALT $ 3x the upper limit of normal of 39.7 
compared to other genotypes.40 A frequent association 
Table 2. Discontinuation rates due to Aes.
Discontinuation due to adverse events (%) pazopanib27 sunitinib8,59 sorafenib60 Axitinib57
Prior cytokine 19 11 NS 4*
Treatment naïve 12 19 11 NA
note: *Includes prior anti-veGF treatment.
Abbreviations: NS, Not stated; NA, Not available.vasudev and Larkin
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between pazopanib-induced hyperbilirubinaemia and 
Gilbert’s syndrome UGTIAI polymorphism has also 
been reported, suggesting that in patients with isolated 
rises in bilirubin, some may represent benign manifes-
tation of Gilbert’s syndrome.41
patient selection and Monitoring 
Response
Response and toxicity to pazopanib, and other TKIs, 
remains unpredictable in individual patients. There are 
currently no validated markers to allow selection of 
patients destined to gain maximal clinical benefit. At 
a clinical level, models that determine prognosis have 
been validated in the TKI era but such nomograms do 
not predict for response.42 VHL status and circulating 
levels of angiogenesis-related factors such as VEGF 
have proven unhelpful.43,44 This therefore remains an 
active and ongoing area of research in RCC.
Translational studies as part of large clinical trials 
are important in this regard. Amongst the 585 patients 
who received pazopanib within the phase II and III 
studies of this drug, 397 (68%) consented to a sample 
of  blood  being  taken  for  germline  analysis. These 
samples have now been analysed, evaluating 27 poly-
morphisms amongst 13 genes, including those related 
to metabolism (CYP3A4/5), transport (ABCB1) and 
angiogenesis (VEGFA/IL-8/FGF2). Two interleukin-8 
(IL-8)  polymorphisms  (276TT/-251AA),  linked  to 
increased gene expression, were associated with a sig-
nificantly shorter median PFS (27 weeks) than those 
carrying the wild-type genotype (48 weeks) (HR 1.8; 
P = 0.01). A variant of the HIF1 A genotype was simi-
larly correlated with shorter PFS. Importantly, these 
correlations  were  not  observed  in  placebo  treated 
patients, suggesting that these   markers may indeed 
be predictive rather than simply prognostic. IL-8 has 
been identified as a potential driver of resistance to 
TKIs at both a pre-clinical and clinical level,16,45 mak-
ing the results highly biologically relevant.30
Plasma  samples  from  pazopanib  and  placebo 
treated patients within the phase III study of pazopanib 
have also been analysed for levels of cytokines and 
angiogenesis  factors  including  HGF,  IL-6,  IL-8, 
TIMP-1, VEGF, E-Selectin and OPN correlated with 
outcome. 344 patient samples were examined. Higher 
levels of IL-8 (P , 0.006), HGF (P , 0.01), OPN 
(P , 0.001) and TIMP-1 (P , 0.006) were associated 
with shorter PFS amongst pazopanib treated patients. 
However, with the exception of IL-6, a similar cor-
relation was found amongst placebo treated patients. 
Thus the majority of markers appear to be prognostic 
whilst baseline serum IL-6 levels may predict for PFS 
amongst pazopanib treated patients.46
It  is  intriguing  that  certain  toxicities  such  as 
hypertension  may  serve  as  surrogate  biomarkers 
of  response  to  TKIs.  In  a  retrospective  analysis 
of  .500  patients  treated  with  sunitinib,  hyper-
tension  (HTN)  (defined  as  systolic  blood  pres-
sure  (SBP)  .140  mmHg  or  diastolic  BP  (DBP) 
of  .90  mmHg  was  significantly  associated  with 
response rate and survival. Amongst patients with 
HTN defined by SBP, objective response rate and 
OS were 54.8% and 30.9 months respectively vs. 
8.7%  and  7.2  months  in  patients  without  HTN 
(P , 0.001).47 Prospective studies are now planned 
that will titrate dose of TKI until development of 
hypertension, to determine whether this improves 
outcome.48 Hypothyroidism and hand-foot syndrome 
(certainly the latter of which would be considered 
an  ‘off-target’  effect)  have  also  been  correlated 
Table 3. Toxicity profile of TKIs (%; all grades).
setting pazopanib27 sunitinib8 sorafenib10 Axitinib57 Tivozanib58
First/second-line First-line second-line second-line First/second-line
Hypertension 40 30 19.5 40 45
Diarrhea 52 61 55 55 12
Anorexia 22 34 22 ,25 5
Fatigue 19 54 34 39 8
Hand-foot syndrome 839 29 56 27 4
Stomatitis – 30 NS 9 4
Nausea 26 52 17 32 NA
vomiting 21 31 NS 24 NA
Abbreviations: NA, Not available; NS, Not stated.TKIs in advanced renal cell carcinoma
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with outcome in sunitinib treated patients.36,49 Their 
low   incidence is unlikely to render them useful in 
pazopanib treated patients however.
Accurately determining whether patients are deriv-
ing benefit from potentially toxic therapy in a timely 
manner  is  important  for  patients  and  future  study 
design.  RECIST  has  been  the  standard  method  of 
treatment evaluation for solid tumors since their intro-
duction in 2000. Whilst validated in the setting of con-
ventional chemotherapeutic agents, their applicability 
to assessing and monitoring response in the targeted 
era  has  been  questioned.  Marked  improvements  in 
survival associated with the TKIs have not been mir-
rored by high response rates as per RECIST criteria 
(sunitinib 31%8; pazopanib 30%27). It may be more 
relevant to examine other parameters such as arterial 
phase density, morphology and size in combination in 
this setting.50–52 Studies to date have been small and 
retrospective and evaluation of these criteria in larger 
numbers in a prospective manner is required.
place in Therapy
Treatment  options  for  patients  with  mRCC  have 
burgeoned in recent years. Three TKIs are currently 
approved. Application for a fourth, axitinib, has been 
submitted by Pfizer to both the FDA and European 
Medicines  Agency  (EMA)  for  use  in  second-line 
  therapy. A  fifth,  tivozanib,  is  in  phase  III  testing. 
A sixth, cediranib, is in phase II second-line   studies. 
Bevacizumab  plus  interferon  is  another  approved 
option  in  first-line  therapy,  as  well  as  the  mTOR 
inhibitor temsirolimus in patients with poor risk dis-
ease. In the second line setting, after anti-VEGF ther-
apy failure, everolimus (another mTOR inhibitor) is 
the only agent currently approved.
Amongst  these  agents,  sunitinib  has  emerged 
as the standard of care and by far the most widely 
used agent in the first-line setting.53 This is based 
on the fact that sunitinib demonstrated superiority 
over interferon-α, the previous standard of care, in 
a phase III randomised trial.8 Such a principle guides 
modern oncological practice. A head to head ran-
domized phase III trial of sunitinib versus pazopanib 
(COMPARZ)  has  recently  completed  recruitment 
and the results are eagerly awaited. In the meantime, 
based on currently available data, should pazopanib 
be considered as an alternative or indeed preferential 
first-line option?
Comparisons of  PFS (Table 1) suggest both sunitinib 
and pazopanib to be equally efficacious. If true, then 
toxicity becomes paramount in determining choice of 
drug. With seemingly lower rates of hand-foot syn-
drome, stomatitis, hypothyroidism and fatigue asso-
ciated with pazopanib, there is certainly a case to be 
made for its first-line use. Indeed both the National 
Comprehensive  Cancer  Network  (NCCN)  and  the 
European Association of Urology (EAU) guidelines 
recommend pazopanib as a first-line option alongside 
sunitinib.54 But extrapolating data in this manner is 
not always reliable. Are the two drugs really equally 
efficacious? And is the toxicity profile of pazopanib 
favorable?  Or  just  different?  There  are  those  that 
argue that in the absence of phase III data demon-
strating superiority of pazopanib over sunitinib, there 
is no justification for its use at present.55 Our cur-
rent approach is to use sunitinib as first-line therapy, 
reserving pazopanib for those patients intolerant of 
the former for whatever reason.
The situation is no clearer for pazopanib in the 
second-line setting. The question of what to use post-
cytokine failure has become largely irrelevant. And 
whilst pazopanib has demonstrated efficacy in such 
patients, so too have sorafenib and axitinib in phase III 
trials. The key question is what to do in patients fol-
lowing anti-VEGF based therapy. Everolimus is the 
current standard of care in this setting, demonstrating 
an improvement in PFS from 1.9 months (placebo) to 
4.9 months (P , 0.001) amongst 416 mRCC patients 
who had received one or two prior lines of treatment.56 
Axitinib has recently shown superiority to sorafenib 
in  a  phase  III  second-line  study  involving  723 
patients pre-treated with one line of therapy includ-
ing cytokines, bevacizumab/interferon, temsirolimus 
or sunitinib, increasing PFS from 4.7 to 6.7 months 
(P , 0.0001). The benefit was not significant how-
ever amongst the subset of patients pre-treated with 
sunitinib (3.4 vs. 4.8 months; P = 0.1).57 No equivalent 
trial data exists for pazopanib, which would now be 
required to show superiority over everolimus and/or 
axitinib. Nevertheless, the NCCN include pazopanib 
as a second-line option following TKI failure, since 
TKI sequencing has been associated with response.18
Future studies
Pazopanib is currently the subject of a number of tri-
als in renal cancer patients that are either planned or vasudev and Larkin
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on going. In the neoadjuvant setting, a phase II study 
is currently recruiting, in which patients will receive 
pazopanib for up to 18 weeks prior to surgery, the 
primary endpoint being rate of partial nephrectomy 
(NCT01158521). In the adjuvant setting, a random-
ized phase III trial is currently recruiting, random-
izing patients between one year of pazopanib versus 
placebo (NCT01235962). An important question is 
whether alternating treatment between two classes 
of drug can postpone or prevent drug resistance. To 
answer this, a randomized phase II study exploring 
the efficacy and feasibility of upfront bi-monthly 
rotations  between  everolimus  and  pazopanib  in 
patients  with  mRCC  is  planned  (NCT01408004). 
A  second  study,  that  is  currently  recruiting,  will 
compare 6 different 2-drug “sequences” of everoli-
mus, bevacizumab, or pazopanib (NCT01217931). 
In the first line metastatic setting, a phase II study 
will  compare  pazopanib  against  temsirolimus  in 
poor  risk  patients  (NCT01392183).  Second-line 
studies after prior VEGF therapy include a study 
involving patients following any one prior VEGF-
TKI (NCT01157091). Finally, early phase studies 
are  currently  recruiting  patients  to  examine  the 
safety of using pazopanib in combination with bev-
acizumab  (NCT01202032)  (NCT00992121)  and 
everolimus (NCT01184326).
conclusions
Pazopanib joins a growing number of agents with 
activity  against  RCC.  Published  data  demonstrate 
its superiority over placebo in treatment naïve and 
cytokine-refractory  patients.  PFS  appears  equiva-
lent and safety profile favorable in comparison to the 
current standard of care, sunitinib. However, results 
from the phase III COMPARZ study comparing these 
agents are still awaited. In the meantime, the place of 
pazopanib in the management of patients remains the 
subject of debate.
The emergence of second-generation TKIs makes 
the future for pazopanib less certain still. Tivozanib, 
for example, shows promising activity and is currently 
in phase III trial testing against sorafenib in treatment 
naïve or cytokine refractory patients with advanced 
clear cell RCC (NCT01030783). This choice of com-
parator, rather than sunitinib, will, however, make the 
results difficult to interpret in terms of current clinical 
practice.
A key issue for all TKIs is the invariable devel-
opment of resistance and studies that are examining 
pazopanib in novel settings such as in combination 
with other drugs and in planned sequences are impor-
tant and likely to help shape the future for this drug 
and patient management in general.
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